SGMO vs. CRIS, SABS, AGEN, BLUE, GRTS, OTLK, LIFE, OMGA, VIGL, and PASG
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Curis (CRIS), SAB Biotherapeutics (SABS), Agenus (AGEN), bluebird bio (BLUE), Gritstone bio (GRTS), Outlook Therapeutics (OTLK), aTyr Pharma (LIFE), Omega Therapeutics (OMGA), Vigil Neuroscience (VIGL), and Passage Bio (PASG). These companies are all part of the "biological products, except diagnostic" industry.
Curis (NASDAQ:CRIS) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment.
Curis has a beta of 3.59, suggesting that its share price is 259% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.
In the previous week, Curis had 10 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 20 mentions for Curis and 10 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.71 beat Curis' score of -0.03 indicating that Curis is being referred to more favorably in the media.
Curis received 249 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 67.65% of users gave Curis an outperform vote while only 62.71% of users gave Sangamo Therapeutics an outperform vote.
30.0% of Curis shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 5.7% of Curis shares are held by insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Curis has a net margin of -486.45% compared to Curis' net margin of -1,749.06%. Curis' return on equity of -182.55% beat Sangamo Therapeutics' return on equity.
Curis has higher earnings, but lower revenue than Sangamo Therapeutics. Curis is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Curis presently has a consensus price target of $37.33, suggesting a potential upside of 196.30%. Sangamo Therapeutics has a consensus price target of $5.67, suggesting a potential upside of 830.95%. Given Curis' higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Curis.
Summary
Curis beats Sangamo Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
